Johnson & Johnson $JNJ Stock: ProShare Advisors LLC Reduces Stake

Posted by Geri Gentry on Nov 3rd, 2026

ProShare Advisors LLC lessened its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 5.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,131,562 shares of the company’s stock after selling 66,943 shares during the quarter. Johnson & Johnson makes up approximately 0.4% of ProShare Advisors LLC’s investment portfolio, making the stock its 29th largest position. ProShare Advisors LLC’s holdings in Johnson & Johnson were worth $299,570,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of JNJ. Silver Coast Investments LLC boosted its position in shares of Johnson & Johnson by 3.8% during the 2nd quarter. Silver Coast Investments LLC now owns 1,066 shares of the company’s stock valued at $271,000 after purchasing an additional 39 shares in the last quarter. Townsend Asset Management Corp NC ADV increased its holdings in Johnson & Johnson by 0.6% during the 2nd quarter. Townsend Asset Management Corp NC ADV now owns 6,418 shares of the company’s stock worth $1,630,000 after purchasing an additional 39 shares in the last quarter. Triumph Capital Management grew its holdings in Johnson & Johnson by 1.6% during the second quarter. Triumph Capital Management now owns 2,531 shares of the company’s stock worth $643,000 after buying an additional 39 shares in the last quarter. Kwmg LLC grew its stake in shares of Johnson & Johnson by 1.7% in the 3rd quarter. Kwmg LLC now owns 2,383 shares of the company’s stock worth $631,000 after acquiring an additional 39 shares in the last quarter. Finally, Cypress Wealth Services LLC grew its position in Johnson & Johnson by 0.4% in the 3rd quarter. Cypress Wealth Services LLC now owns 10,618 shares of the company’s stock worth $2,705,000 after purchasing an additional 39 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, EVP Timothy Schmid sold 33,597 shares of Johnson & Johnson stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the sale, the executive vice president directly owned 25,447 shares in the company, valued at $6,991,308.78. The trade was a 56.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Elizabeth Forminard sold 15,918 shares of the firm’s stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $257.00, for a total value of $4,090,926.00. Following the transaction, the executive vice president directly owned 16,994 shares of the company’s stock, valued at $4,367,458. This represents a 48.37% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 64,515 shares of company stock worth $17,271,766. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Price Performance

JNJ opened at $270.81 on Tuesday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.02 and a quick ratio of 0.74. Johnson & Johnson has a 1 year low of $185.12 and a 1 year high of $282.02. The firm has a market cap of $651.93 billion, a price-to-earnings ratio of 41.03, a PEG ratio of 2.68 and a beta of 0.21. The stock’s 50 day simple moving average is $265.74 and its 200 day simple moving average is $247.22.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, beating analysts’ consensus estimates of $2.53 by $0.06. The company had revenue of $25.40 billion during the quarter, compared to analyst estimates of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The firm’s revenue was up 5.9% compared to the same quarter last year. During the same period in the prior year, the business posted $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, analysts predict that Johnson & Johnson will post 11.12 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be issued a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.0%. The ex-dividend date is Tuesday, November 24th. Johnson & Johnson’s dividend payout ratio is currently 81.21%.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

Positive Sentiment: New real-world and observational analyses presented at the TCT 2026 symposium found lower in-hospital and short-term mortality among high-risk percutaneous coronary intervention patients supported by Impella pumps. The findings covered 1,379 patients in U.S. and European hospitals and compared favorably with results from the CHIP-BCIS3 study. Data Show Positive Survival and Patient Outcomes with Best-Practice Impella Support in HRPCI
Positive Sentiment: A separate report cited a 94% success rate in a coronary-device trial, adding to evidence that Impella could improve outcomes in complex coronary procedures. Stronger clinical support could help J&J expand adoption of the devices and reinforce its medical-technology growth strategy. Johnson & Johnson reports 94% success rate in trial of coronary artery device
Positive Sentiment: Clinicians also reviewed progress in the ongoing PROTECT IV trial, which is expected to provide additional evidence for Impella-supported high-risk procedures. Further positive results could improve confidence in the product’s long-term commercial potential. What Is Johnson & Johnson Signaling With Its New Impella Heart Pump Data?
Neutral Sentiment: Exchange-traded funds purchased approximately $35.1 million of JNJ shares on October 29, suggesting institutional demand, though the transaction alone does not establish a lasting change in investor sentiment. ETFs Are Buying Johnson & Johnson
Negative Sentiment: Some coverage questioned whether JNJ is fully valued after strong recent performance, including a reported 6.71% 30-day return and 31.76% year-to-date gain. That raises the risk that positive Impella news is already reflected in the stock and could limit near-term upside. Johnson & Johnson As Impella Data Fuels The Story, Is The Stock Fully Valued?

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the company. The Goldman Sachs Group reaffirmed a “buy” rating and set a $282.00 target price on shares of Johnson & Johnson in a research report on Thursday, July 16th. TD Cowen restated a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, October 20th. Citigroup increased their price target on shares of Johnson & Johnson from $298.00 to $303.00 and gave the stock a “buy” rating in a report on Monday, October 5th. Royal Bank Of Canada dropped their price objective on Johnson & Johnson from $290.00 to $280.00 and set an “outperform” rating for the company in a research note on Wednesday, October 14th. Finally, Bank of America reissued a “neutral” rating and issued a $278.00 price target on shares of Johnson & Johnson in a research note on Tuesday, September 29th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $275.92.

Check Out Our Latest Report on Johnson & Johnson

Johnson & Johnson Company Profile

(Free Report)

Johnson & Johnson (NYSE: JNJ) is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.